Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHS-1420 vs HUMIRA in healthy Chinese adults
NCT07147257Phase 1Completed
- Sponsor
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of adalimumab aqvh (2 arms), sponsored by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Primary endpoints: Areas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity and Maximum Serum Drug Concentration. Started Feb 2025; status: completed.
02
Drugs
adalimumab aqvh
Beyond the preview
Go deeper on NCT07147257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147257.